

To the OMX  
Announcement No. 39-07 / Copenhagen, 26 November 2007

**TopoTarget A/S**  
Symbion  
Fruebjergvej 3  
DK 2100 Copenhagen Ø  
Denmark  
Tel: +45 39 17 83 92  
Fax: +45 39 17 94 92  
CVR-nr: 25695771

[www.topotarget.com](http://www.topotarget.com)

## **TopoTarget and CuraGen announce presentations on Belinostat at the upcoming American Society of Hematology 49<sup>th</sup> Annual Meeting**

**Copenhagen, Denmark – 26 November 2007 – TopoTarget A/S (OMX: TOPO) and CuraGen Corporation (Nasdaq: CRGN)** a clinical-stage biopharmaceutical company focused on oncology, have announced today that updated preliminary clinical trial results from the Phase II study of belinostat for T-cell lymphomas, and new preclinical data evaluating belinostat on pediatric leukemia cell lines, will be presented at the 2007 American Society of Hematology (ASH) 49<sup>th</sup> Annual Meeting in Atlanta, GA, USA, on Monday, December 10, 2007.

The presentation details are as follows:

Title: "Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study"  
Date/Time: Monday, December 10, 2007, 5:00 – 7:00 PM EST  
Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models-Diffuse Large Cell Lymphoma and T-Cell Lymphoma  
Poster board: 672-II  
Abstract: 3453

Title: "Investigation of the Efficacy of PXD101 (Belinostat) on Primary Leukaemic Cells and Cell Lines as a Novel Agent for Childhood Acute Lymphoblastic Leukaemia (ALL)"  
Date/Time: Monday, December 10, 2007, 5:00 – 7:00 PM EST  
Session: Acute Lymphocytic Leukemia: Biology and Pathophysiology  
Poster board: 12-III  
Abstract: 2793

These abstracts are currently available online at <http://www.abstracts2view.com/hem07>. Following the presentations the posters will be made available on TopoTarget's website at [www.topotarget.com](http://www.topotarget.com).

Today's news does not change TopoTarget's full-year financial guidance for 2007.

**TopoTarget A/S**



TopoTarget and CuraGen announce presentations on Belinostat at the upcoming American Society of Hematology 49<sup>th</sup> Annual Meeting

For further information, please contact:

Dr. Peter Buhl Jensen	Telephone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22

Ulla Hald Buhl	Telephone	+45 39 17 83 92
Director IR & Communications	Mobile	+45 21 70 10 49

## Background information

### About Belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade® (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.

Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell lymphomas, AML, mesothelioma, soft tissue sarcoma, MDS, and liver, colorectal, and ovarian cancers, either alone or in combination with anti-cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.

### About TopoTarget

TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget's first product on the market. For more information, please refer to [www.topotarget.com](http://www.topotarget.com).

### About CuraGen

CuraGen Corporation (NASDAQ: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including the histone deacetylase inhibitor, belinostat, and the antibody-drug conjugate, CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit [www.curagen.com](http://www.curagen.com).

### TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current



TopoTarget and CuraGen announce presentations on Belinostat at the upcoming American Society of Hematology 49<sup>th</sup> Annual Meeting

expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

